Diagnostic study reveals PSMA-PET detects M1 disease in 55% of patients with nonmetastatic castration-resistant prostate cancer, suggesting a need for treatment guidance trials.
PSMA-PET detected any disease in nearly all patients and M1 disease in 55% of patients previously diagnosed with nmCRPC, including subgroups with PSADT of ≤10 months and Gleason score of ≥8. The value of PSMA-PET imaging for treatment guidance should be tested in future studies.
No takes yet. Share an insight, caveat, or question.
Fendler et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: